MS and Demyelinating Disorders

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 3, 2021.

A discussion on the integration of newer therapies, like cladribine, into the treatment landscape for relapsing multiple sclerosis (MS), and insight regarding what is currently understood about risks of disease progression and relapse.

An overview of clinical trial data supporting the use of cladribine as treatment for relapsing multiple sclerosis (MS).

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed unmet needs of care for patients with neuromyelitis optica spectrum disorder.

The neuro-ophthalmologist at UT Southwestern further discussed the high cost of treatment for patients with neuromyelitis optica spectrum disorder and the need to improve access to care.

The neuro-ophthalmologist at UT Southwestern Medical Center discussed optical coherence tomography and antibody detection technology used to diagnose optic neuritis associated with NMOSD.

Here's what is coming soon to NeurologyLive.

The director of Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided context on challenges within the NMOSD space and what’s next following the first-approved therapies.

Discussing NMOSD’s relation to AQP4 and pattern enhancement on MRIs, the neuro-ophthalmologist at UT Southwestern Medical Center further commented on the importance of early diagnosis.

Bruce Cree, MD, PhD, clinical research director of the UCSF Multiple Sclerosis Center, provided context on the status of patient education efforts and clinical development for neuromyelitis optica spectrum disorder.

A literature review evaluated phase 3 trials in patients with secondary progressive multiple sclerosis, including trials dating back to 1990, to establish the most important measures used.

Neurology News Network for the week ending August 28, 2021.

The neuro-ophthalmologist from UT Southwestern Medical Center provided her opinion on the state of care for patients with NMOSD and associated optic neuritis technology.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 27, 2021.

The results support continued development of tolebrutinib 60 mg in phase 3 trials for MS, based on the well-established relationship between reductions of Gadolinium-enhancing lesions and relapse rates.

The director of Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the most notable recent advances that has propelled care for patients with NMOSD.

Health care professionals who work in the field of neurology comment on their experience using interferon therapies and glatiramer acetate as treatment for relapsing multiple sclerosis.

The rationale for early treatment of multiple sclerosis, and an overview of limitations that impact the management of relapsing multiple sclerosis.

The Swedish treatment strategy—one of mostly induction—was associated with a 24% reduction in the rate of reaching EDSS score of 3 and a 25% reduction in the rate of reaching an EDSS score of 4.

Watch the "COVID-19 and MS Summit – Infections and Immunizations in the Era of COVID-19" broadcast today!

The clinical research director of the UCSF Multiple Sclerosis Center shared his perspective on the history of clinical care for neuromyelitis optica spectrum disorder in light of 3 recent FDA approvals.

Investigators found that frequency of MOG-Ab associated NMOSD was not significantly different between Asian and Caucasian populations despite the prevalence of NMOSD in Asian regions.

The rate of patients demonstrating impairment on cognitive assessments such as CVLTII, BVMT-R, and SDMT significantly decreased after treatment with fingolimod at 5-year follow-up.

A recent systematic review investigated the use of virtual reality as a therapeutic tool compared to conventional interventions, finding its use may improve quality of life, fatigue, and balance.

Lesions in the canalicular and intracranial optic nerve, area postrema, medulla, and cervical spinal cord were prominent in patients with aquaporin-4–NMOSD.